Selexipag

General

Type : Sulfonyl, Sulfur Compound, Not A\/B H target, Pro-Drug, Drug

Chemical_Nomenclature : 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide

Canonical SMILES : CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3

InChI : InChI=1S\/C26H32N4O4S\/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22\/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)

InChIKey : QXWZQTURMXZVHJ-UHFFFAOYSA-N

Other name(s) : NS-304  ||  Uptravi  ||  NS 304  ||  ACT-293987


MW : 496.62

Formula : C26H32N4O4S

CAS_number : 475086-01-2

PubChem : 9913767

UniChem : QXWZQTURMXZVHJ-UHFFFAOYSA-N

Target

Families : Carb_B_Chordata

References (1)

Title : Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro - Imai_2019_J.Pharm.Sci_108_1027
Author(s) : Imai S , Ichikawa T , Sugiyama C , Nonaka K , Yamada T
Ref : J Pharm Sci , 108 :1027 , 2019
Abstract :
PubMedSearch : Imai_2019_J.Pharm.Sci_108_1027
PubMedID: 30267780